Nucleic acid products and methods of administration thereof

Patent metadata

Field	Value
Publication number	US-10369233-B2
Application number	US-201816030675-A
Country	US
Kind code	B2
Filing date	Jul 9, 2018
Priority date	Aug 17, 2016
Publication date	Aug 6, 2019
Grant date	Aug 6, 2019

Abstract

The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.

First claim

What is claimed is:

1. A composition comprising a synthetic RNA encoding a gene-editing protein that targets an immune checkpoint molecule gene, wherein the gene-editing protein comprises:
(a) a DNA-binding domain comprising a plurality of repeat sequences and at least one of the repeat sequences comprises the amino acid sequence: LTPvQVVAIAwxyzGHGG (SEQ ID NO: 629) and is between 36 and 39 amino acids long, wherein:
“v” is Q, D or E,
“w” is S or N,
“x” is H, N, or I,
“y” is D, A, I, N, G, H, K, S, or null, and
“z” is GGKQALETVQRLLPVLCQD (SEQ ID NO: 630) or GGKQALETVQRLLPVLCQA (SEQ ID NO: 631); and

(b) a nuclease domain comprising a catalytic domain of a nuclease.

2. The composition of claim 1 , wherein the nuclease domain is capable of forming a dimer with another nuclease domain.

3. The composition of claim 1 , wherein the immune checkpoint molecule is selected from PD-1, PD-L1, PD-L2, CTLA-4, ICOS, LAG3, OX40, OX40L, and TIM3.

4. The composition of claim 1 , wherein the synthetic RNA comprises one or more non-canonical nucleotides, the one or more non-canonical nucleotides comprise one or more of 5-hydroxycytidine, 5-methylcytidine, 5-hydroxymethylcytidine, 5-carboxycytidine, 5-formylcytidine, 5-methoxycytidine, pseudouridine, 5-hydroxyuridine, 5-methyluridine, 5-hydroxymethyluridine, 5-carboxyuridine, 5-formyluridine, 5-methoxyuridine, 5-hydroxypseudouridine, 5-methylpseudouridine, 5-hydroxymethylpseudouridine, 5-carboxypseudouridine, 5-formylpseudouridine, and 5-methoxypseudouridine.

5. The composition of claim 1 , wherein the synthetic RNA comprises a 5′ cap structure.

6. The composition of claim 1 , wherein the synthetic RNA comprises a 5′-UTR comprising a Kozak consensus sequence.

7. The composition of claim 1 , wherein the synthetic RNA comprises a 5′-UTR comprising a sequence that increases RNA stability in vivo.

8. The composition of claim 1 , wherein the synthetic RNA comprises a 3′-UTR comprising a sequence that increases RNA stability in vivo.

9. The composition of claim 1 , wherein the synthetic RNA comprises a 3′ poly(A) tail.

10. The composition of claim 4 , wherein the one or more non-canonical nucleotides comprises 5-methoxyuridine.

Assignees

• Factor Bioscience Inc

Inventors

• Angel Matthew
• Rohde Christopher

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• C12N9/22

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title